Medicortex Finland is dedicated to improving the diagnosis, treatment and prevention of acute neurodegenerative
conditions, and is currently focused on developing a novel multiplex treatment for traumatic brain injury (TBI) as well as brain injury due to stroke.

Board and Management

The company's founder is Dr. Adrian Harel, an experienced neurobiologist with an impressive track record in leadership of early-stage drug discovery companies and business management. His collaboration with renowned experts in medicinal chemistry promises to generate a successful pipeline of innovative therapeutic molecules and diagnostic biomarkers.

Management Team

Medicortex's CEO, Dr. Adrian Harel, holds a PhD in Neurobiology, from the Weizmann Institute of Science, and was a postdoctoral at Washington University. Dr. Harel has many years of experience in the pharmaceutical and biotech industry. Dr. Harel has extensive Drug R&D know-how and GMP production and manufacturing knowledge. He combines a broad scientific education with extensive industry experience.

Medical Director Mårten Kvist has an MD from the University of Helsinki, Finland, and MD/PhD at the University of Turku, Finland. He is an Associate Professor (Docent) in General Practice at the University of Turku and in public Health at the University of Lapland.

Head of R&D Lasse Välimaa has a PhD in Molecular Biotechnology and Diagnostics at the University of Turku, Finland. His scientific background is in the R&D of bioanalytical methods and medical diagnostics. 

Clinical Research Coordinator Oskar Haavisto has a Bs.c in biochemistry from the University of Turku. He´s planning to graduate as a Master of Molecular Biotechnology and Diagnostics by 2020. 

Our CFO is KLT-accountant Marjukka Iitti. Also a partner and member of the board in Tili-Vinkki Oy.

Scientific Advisory Board

Professor Heikki Rauvala - Chairman of the SAB, a research director at the Neuroscience Center of University of Helsinki, Finland. Dr. Rauvala has published 213 frequently cited publications relating to his primary research interests; development, plasticity and regeneration of the central nervous system; injuries of the central nervous system; behavioral disorders. 

Professor Antti Kaipia - Professor of Surgery at University of Turku, Finland, and Chief Physician. Dr. Kaipia has a vast experience in surgery and in clinical practice at a central hospital.

Dr. Lauri Kangas - Senior Adviser at a pharmaceutical company, and Chief Scientific Officer, Finland.

Associate professor Timo Kurki - Neuroradiologist and Chief of Medical Imaging at Terveystalo Oy, Finland.

Professor Risto O. Roine - Professor and Chairman, Division of Clinical Neurosciences, Turku University Hospital and University of Turku, Finland. National coordinator for an EU Biomed project with a 2.2-million-euro budget. Dr. Roine has been a Principle Investigator in 15 studies relating to secondary neurological damage and its treatment.

Board of Directors

Chariman of the Board - Dr. Adrian Harel

Member Associate Professor Mårten Kvist, MD, PhD, Medical Director

Member Tom Palenius, Director, Services for Startup Companies at Turku Science Park Oy.